J M Gasent

Summary

Country: Spain

Publications

  1. pmc Durable complete remission of a brainstem glioma treated with a combination of bevacizumab and cetuximab
    Joan Manel Gasent Blesa
    Department of Medical Oncology, Hospital de Denia, Marina Salud, Denia, Spain
    Case Rep Oncol 5:676-81. 2012
  2. pmc PSA Response to Lenalidomide Therapy in a Pre-Treated Patient with Metastatic Prostate Cancer Refractory to Hormones and Chemotherapy: A Case Report
    Joan Manel Gasent Blesa
    Departamento de Oncología Médica y, Universidad de Alicante, Alicante, Y, Valencia, Espana
    Case Rep Oncol 5:181-6. 2012
  3. pmc Cell-cell fusion as a potential target in cancer therapy
    Jm Gasent Blesa
    Hospital General Universitari Marina Alta, Denia, Plana de l Est no 5, Alacant, Spain
    Ecancermedicalscience 3:145. 2009
  4. pmc Isolated colorectal liver metastases locally progressing after stereotactic body radiotherapy rescued with surgery
    J M Gasent Blesa
    Hospital General Universitari Marina Alta, Denia, Alacant, Spain
    Curr Oncol 16:76-80. 2009
  5. pmc Old and new insights in the treatment of thyroid carcinoma
    Joan Manel Gasent Blesa
    Departament d Oncologia Mèdica, Hospital de Denia, Marina Salud, Partida de Beniadlà s n, Denia, Alacant, Spain
    J Thyroid Res 2010:279468. 2010
  6. doi request reprint Phase II trial of concomitant neoadjuvant chemotherapy with oxaliplatin and capecitabine and intensity-modulated radiotherapy (IMRT) in rectal cancer
    Joan Manel Gasent Blesa
    Hospital de Denia, Partida de Beniadlà s n Dénia MarinaSalud, Denia, Alicante, Spain
    J Gastrointest Cancer 43:553-61. 2012
  7. doi request reprint [Experience with sunitinib in hormone-resistant metastatic prostate cancer that is unresponsive to docetaxel]
    J M Gasent
    Hospital de Denia, Alicante, Espana
    Actas Urol Esp 35:57-60. 2011
  8. doi request reprint Phase II trial of oxaliplatin and capecitabine after progression to first-line chemotherapy in androgen-independent prostate cancer patients
    Joan Manel Gasent Blesa
    Hospital de Denia, Marina Salud, Alicante, Spain
    Am J Clin Oncol 34:155-9. 2011
  9. doi request reprint Melanoma: from darkness to promise
    Joan Manel Gasent Blesa
    Medical Oncology Service, Hospital Marina Alta de Denia, Alacant, Spain
    Am J Clin Oncol 34:179-87. 2011
  10. doi request reprint PSA decrease with fulvestrant acetate in a hormone-resistant metastatic prostate cancer patient
    Joan M Gasent Blesa
    Department of Medical Oncology, Hospital de Denia, Alacant, Spain
    Onkologie 33:57-9. 2010

Collaborators

  • J B Laforga
  • Carlos Rodriguez-Galindo
  • Joan Manel Gasent Blesa
  • Vicente Alberola Candel
  • J M Gasent Blesa
  • Mariano Provencio Pulla
  • V Alberola Candel
  • Jose Luis Sanchez
  • Miguel Peris Godoy
  • Juan Bautista Laforga Canales
  • Enrique Grande Pulido
  • E Esteban Gonzalez
  • Sara Blasco Mollá
  • María Fonfría Esparcia
  • José Miguel Sempere Ortells
  • Balbino Mancheño Magán
  • Joan M Gasent Blesa
  • Jm Gasent Blesa
  • J Laforga Canales
  • M Provencio Pulla
  • Juan Laforga Canales
  • Antonio Alberola
  • Vicent Giner Bosch
  • Miguel Soler Tortosa
  • Javier Garde Noguera
  • Adrian Munilla Das
  • Vicente Giner-Bosch
  • Pablo Cerezuela Fuentes
  • Vicente Giner Marco
  • Miguel Grimalt Arrom
  • Patricia Martin Rico
  • S Martin Algarra
  • F Peiró Monzó
  • J Bertelli Puche
  • Va Candel
  • A Alberola Soler
  • K Pachmann
  • Christof Semler
  • Maria Rosa Pérez Antolí
  • Pedro Romero Pérez
  • Walid Rafie Macketli
  • Carlos Solano Vercet
  • J Vidal Martínez
  • Francisco José Merenciano Cortina
  • R Gisbert Criado
  • Manuel Amat Cecilia

Detail Information

Publications19

  1. pmc Durable complete remission of a brainstem glioma treated with a combination of bevacizumab and cetuximab
    Joan Manel Gasent Blesa
    Department of Medical Oncology, Hospital de Denia, Marina Salud, Denia, Spain
    Case Rep Oncol 5:676-81. 2012
    ..First, the potential target of the cancer stem cells (CSCs) with these two antibodies, and second, the potential recruitment of the immune system to directly pursue the CSCs...
  2. pmc PSA Response to Lenalidomide Therapy in a Pre-Treated Patient with Metastatic Prostate Cancer Refractory to Hormones and Chemotherapy: A Case Report
    Joan Manel Gasent Blesa
    Departamento de Oncología Médica y, Universidad de Alicante, Alicante, Y, Valencia, Espana
    Case Rep Oncol 5:181-6. 2012
    ..It is important to emphasize that it was not associated with hematologic toxicity...
  3. pmc Cell-cell fusion as a potential target in cancer therapy
    Jm Gasent Blesa
    Hospital General Universitari Marina Alta, Denia, Plana de l Est no 5, Alacant, Spain
    Ecancermedicalscience 3:145. 2009
    ..Not much is known about the role of syncytin in cancer, but the existing data call for more intense research. Its retroviral origin and particular tissue distribution make syncytin an interesting potential target in cancer therapy...
  4. pmc Isolated colorectal liver metastases locally progressing after stereotactic body radiotherapy rescued with surgery
    J M Gasent Blesa
    Hospital General Universitari Marina Alta, Denia, Alacant, Spain
    Curr Oncol 16:76-80. 2009
    ..Here, we present the clinical case of a patient with a solitary liver metastasis initially treated with sbrt that was rescued with surgery when a local recurrence was detected...
  5. pmc Old and new insights in the treatment of thyroid carcinoma
    Joan Manel Gasent Blesa
    Departament d Oncologia Mèdica, Hospital de Denia, Marina Salud, Partida de Beniadlà s n, Denia, Alacant, Spain
    J Thyroid Res 2010:279468. 2010
    ..Recently, we have assisted to the development of new agents for the treatment of this disease with unexpected good results. Here we present a review with the old and new methods for the treatment of this disease...
  6. doi request reprint Phase II trial of concomitant neoadjuvant chemotherapy with oxaliplatin and capecitabine and intensity-modulated radiotherapy (IMRT) in rectal cancer
    Joan Manel Gasent Blesa
    Hospital de Denia, Partida de Beniadlà s n Dénia MarinaSalud, Denia, Alicante, Spain
    J Gastrointest Cancer 43:553-61. 2012
    ....
  7. doi request reprint [Experience with sunitinib in hormone-resistant metastatic prostate cancer that is unresponsive to docetaxel]
    J M Gasent
    Hospital de Denia, Alicante, Espana
    Actas Urol Esp 35:57-60. 2011
    ..One of the options of compassionate use currently available is the use of Sunitinib. We present a joint preliminary experience with the use of Sunitinib in this clinical case...
  8. doi request reprint Phase II trial of oxaliplatin and capecitabine after progression to first-line chemotherapy in androgen-independent prostate cancer patients
    Joan Manel Gasent Blesa
    Hospital de Denia, Marina Salud, Alicante, Spain
    Am J Clin Oncol 34:155-9. 2011
    ..However, there is no agent proven as effective after progression to standard docetaxel-based therapy. Platins and capecitabine have shown activity in this setting...
  9. doi request reprint Melanoma: from darkness to promise
    Joan Manel Gasent Blesa
    Medical Oncology Service, Hospital Marina Alta de Denia, Alacant, Spain
    Am J Clin Oncol 34:179-87. 2011
    ..New targeted agents have changed the standard of care of other solid tumor types like breast cancer. Here, we discuss the new advances and achievements in the treatment of this highly resistant disease...
  10. doi request reprint PSA decrease with fulvestrant acetate in a hormone-resistant metastatic prostate cancer patient
    Joan M Gasent Blesa
    Department of Medical Oncology, Hospital de Denia, Alacant, Spain
    Onkologie 33:57-9. 2010
    ..Fulvestrant has shown activity inhibiting estrogen receptor dimerization, and the androgen receptor has been shown to stimulate growth in prostate cancer cell lines...
  11. doi request reprint Colorectal cancer: response to sunitinib in a heavily pretreated colorectal cancer patient
    Joan Manel Gasent Blesa
    Medical Oncology Department, Hospital Marina Alta Denia, Alicante, Spain
    Anticancer Drugs 21:S23-6. 2010
    ..The patient is still under sunitinib treatment and has recovered his normal daily activity...
  12. ncbi request reprint Management of platinum-resistant ovarian cancer with the combination of pemetrexed and gemcitabine
    J M Gasent Blesa
    Medical Oncology Department, Hospital de Denia Marina Salud, Denia, Alacant, Spain
    Clin Transl Oncol 11:35-40. 2009
    ..Platinum resistant ovarian cancer is a current challenge in Oncology. Current approved therapies offer no more of a 20% of response. New therapeutic options are urgently needed...
  13. ncbi request reprint Young male patient with bilateral synchronous testicular germ cell tumour. Considerations for partial orchiectomy
    Joan Manel Gasent Blesa
    Medical Oncology Department, Hospital de Denia Marina Salud, Denia, Alicante, Spain
    Clin Transl Oncol 10:850-2. 2008
    ..After pathology review, the margin of the partial orchiectomy was considered affected, and an inguinal orchiectomy was planned. Options for testis-sparing surgery are discussed...
  14. ncbi request reprint Langerhans cell histiocytosis
    Joan Manel Gasent Blesa
    Hospital General Universitari Marina Alta, Denia, Alacant, Spain
    Clin Transl Oncol 10:688-96. 2008
    ..Here we present a literature review on all of the aspects of the disease, treatment approaches and existing protocols, and finally an adult clinical case...
  15. ncbi request reprint Circulating tumor cells in breast cancer: methodology and clinical repercussions
    J M Gasent Blesa
    Hospital General Universitari Marina Alta, Denia, Alacant, Spain
    Clin Transl Oncol 10:399-406. 2008
    ..Extremely sensitive techniques are available that are easily applied to peripheral blood samples, which might provide enormous research possibilities in this area...
  16. ncbi request reprint Screening and chemoprevention in lung cancer
    J M Gasent Blesa
    Dpto Oncología Médica, Hospital General Universitario Marina Alta, Denia, Alacant, Spain
    Clin Transl Oncol 10:274-80. 2008
    ..At the present time, the results obtained have not been encouraging and we do not have a clear strategy either for early diagnosis or for the use of chemopreventive agents...
  17. doi request reprint Encapsulated apocrine papillary carcinoma of the breast: case report with clinicopathologic and immunohistochemical study
    J B Laforga
    Department of Pathology, Hospital de Denia, Alicante, Spain
    Diagn Cytopathol 39:288-93. 2011
    ..To the best of our knowledge, this is the first report of EPC apocrine variant with cytologic and immunohistochemical study. This lesion must be included in the list of apocrine lesions of the breast...